Filing Details
- Accession Number:
- 0001209191-20-007104
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-06 11:27:57
- Reporting Period:
- 2020-02-04
- Accepted Time:
- 2020-02-06 11:27:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1787306 | Arcutis Biotherapeutics Inc. | ARQT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1365617 | J Patrick Heron | 601 Union Street, Suite 3200 Seattle WA 98101 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-04 | 6,360,272 | $0.00 | 6,869,304 | No | 4 | C | Indirect | By: Frazier Life Sciences VIII, L.P. |
| Common Stock | Acquisiton | 2020-02-04 | 2,099,019 | $0.00 | 8,968,323 | No | 4 | C | Indirect | By: Frazier Life Sciences VIII, L.P. |
| Common Stock | Acquisiton | 2020-02-04 | 1,074,467 | $0.00 | 10,042,790 | No | 4 | C | Indirect | By: Frazier Life Sciences VIII, L.P. |
| Common Stock | Acquisiton | 2020-02-04 | 500,000 | $17.00 | 10,542,790 | No | 4 | P | Indirect | By: Frazier Life Sciences VIII, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By: Frazier Life Sciences VIII, L.P. |
| No | 4 | C | Indirect | By: Frazier Life Sciences VIII, L.P. |
| No | 4 | C | Indirect | By: Frazier Life Sciences VIII, L.P. |
| No | 4 | P | Indirect | By: Frazier Life Sciences VIII, L.P. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2020-02-04 | 6,360,272 | $0.00 | 6,360,272 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2020-02-04 | 2,099,019 | $0.00 | 2,099,019 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2020-02-04 | 1,074,467 | $0.00 | 1,074,467 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering.
- The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his pecuniary interest therein, if any.
Billionaire Hedge Funds
